Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 13,929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Pain, Post-operative, Third Molar, Oral Surgery, Pain, Acute
Interventions: Ketorolac, Oxycodone, Acetaminophen, Ibuprofen, Hydrocodone; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 44 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Asthma, Vitamin D Deficiency
Interventions: Vitamin D2 + vitamin D3, Vitamin D3; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Moderate to Severe Traumatic Brain Injury
Interventions: Fresh Frozen Plasma (FFP); Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epilepsy
Interventions: BIA 2-093, Moxifloxacin, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Gastroparesis
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions: Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ventura, California

Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions: Lonapegsomatropin, Placebo, Somatropin; Drug · Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 23 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more

Conditions: Obesity, Diabetes
Interventions: Time restricted feeding; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 389
States / cities: Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 3 more

Conditions: Major Depressive Disorder
Interventions: R228060, Placebo and Paroxetine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Traumatic Brain Injury, Head Injury, Head Injuries, Closed, Brain Hemorrhage, Traumatic, Brain Edema, Intracranial Edema
Interventions: Road-to-recovery; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mild Cognitive Impairment (MCI)
Interventions: CogMed; Other
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Interventions: EEG Neurofeedback; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Vaginal Odor
Interventions: Orally-administered probiotic, Placebo; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Methamphetamine Dependence
Interventions: Modafinil; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Lafayette, California • San Francisco, California

Conditions: Tongue Neoplasms, Tongue Cancer, Oral Cancer
Interventions: Palatal Augmentation Prosthesis (PAP), Articulation Therapy; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Substance Related Disorders, Mental Illness
Interventions: Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition), Getting To Outcomes; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Bedford, Massachusetts + 1 more

Conditions: Generalized Anxiety Disorder
Interventions: Troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 53
States / cities: Little Rock, Arkansas • Colton, California • Encino, California + 48 more

Conditions: Radiculopathy
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Phoenix, Arizona • Denver, Colorado • Plantation, Florida + 9 more

Conditions: Overactive Bladder (OAB)
Interventions: Zinc Citrate Oral Capsule, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 21 Years to 100 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Healthy, Hepatic Insufficiency
Interventions: BI 685509, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Semantic Dementia
Interventions: Verdiperstat; Drug
Lead sponsor: Peter Ljubenkov, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more

Search by objective public record fields.

Controlled Trial to Determine Most Effective Post-Operative Analgesia After Third Molar Extraction

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial

FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Buspirone for Early Satiety and Symptoms of Gastroparesis

Trial of Combination Therapy to Treat COVID-19 Infection

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Time Restricted Feeding (4-hour Versus 6-hour) for Weight Loss in Obese Adults

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

Setting Families on a Positive Path to Recovery After Pediatric TBI: Road-to-Recovery

Working Memory Training in Patients with Mild Cognitive Impairment

Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia

The Effects of an Orally-Administered Probiotic on Vaginal Symptoms

A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence

Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue

MISSION-Vet HUD-VASH Implementation Study

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology